Amneal Pharmaceuticals announced the availability of Over the Counter, or OTC, Naloxone Hydrochloride, or Naloxone HCI, Nasal Spray, USP, 4mg, following Abbreviated New Drug Application, or ANDA, approval from the FDA. Amneal’s Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC Narcan HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues
- Bausch suit creates added uncertainty on B+L spin, says TD Cowen
- Bausch Health files patent lawsuit against Amneal Pharmaceuticals
- Amneal receives FDA approval for ciprofloxacin, dexamethasone otic suspension
- Amneal Pharmaceuticals price target raised to $8 from $6 at Piper Sandler
